Cogent Neuroscience, Inc.

Cogent Neuroscience, Inc. (“Cogent”) is a privately-held biopharmaceutical company developing drugs for diseases and disorders of the Central Nervous System. The Company utilizes a technical platform first developed at Duke University by two of the Company’s founders. The Company combines the power of genomics with proprietary functional screening technologies to discover pathways to the next generation of treatments for the major diseases and disorders of the brain. The platform employs a biolistic transfection method into living slices of brain tissue to determine gene function in neuronal tissue. The Company has successfully transfected animal tissue and human tissue, identifying several dozen genes as neuroprotective.  Using this unique screening technology, Cogent is mapping the regulatory structure of the brain and utilizing the resulting information to develop products to treat major neuronal diseases.

Cogent contacted Century Capital before the second round of investment to assist the Company in further refining its business plan and strategic plan as well as to initiate and execute development and licensing agreements with pharmaceutical companies.  Century Capital began working with Cogent in April 2000.  Century Capital has advised the company during the following transactions:

• In September 2000, Century Capital initiated discussions with a major pharmaceutical company regarding the establishment of a strategic alliance.  This led to the creation of a joint venture between Cogent and the pharmaceutical company in December 2000 focused on Huntington’s disease. In conjunction with this transaction, the pharmaceutical company provided the joint venture and Cogent with research and development funding and made an equity investment into the Company.

• In March 2001, Century Capital negotiated a joint venture with a major pharmaceutical company focused on Parkinson’s disease.  In conjunction with this transaction, the pharmaceutical company provided the joint venture and Cogent with research and development funding and made an equity investment into the Company.